Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922941 | 0.85 | PARP1 (0.46) | PARP1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7477385 | 0.81 | PARP1 (0.49) | PARP1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28226825 | 0.81 | PARP1 (0.42) | PARP1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7477457 | 0.79 | TSHR (0.51) | PARP1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12362588 | 0.78 | PARP1 (0.56) | PARP1PKN1PKN2PARP2PARP3 | |
| SCHEMBL5621499 | 0.77 | PARP1 (0.55) | PARP1PARP2PARP3 | |
| SCHEMBL7323651 | 0.77 | PARP1 (1.00) | PARP1PKN1PKN2 | |
| SCHEMBL5620081 | 0.75 | PARP1 (0.53) | PARP1PARP2 | |
| SCHEMBL3194071 | 0.74 | CYP1A2 (0.49) | PARP1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6118671 | 0.74 | FBP1 (0.49) | PARP1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300235-B | Benzimidazole derivative BI321 and preparation method and application thereof | 中国人民解放军东部战区总医院 | 2021-12-21 | — | — | CN | disclosed |
| CN-112300235-B | Benzimidazole derivative BI321 and preparation method and application thereof | 中国人民解放军东部战区总医院 | 2021-12-21 | — | — | CN | disclosed |
| CN-112358517-B | Benzimidazole derivative BI305 and preparation method and application thereof | 中国人民解放军东部战区总医院 | 2021-12-21 | — | — | CN | disclosed |
| CN-112358517-B | Benzimidazole derivative BI305 and preparation method and application thereof | 中国人民解放军东部战区总医院 | 2021-12-21 | — | — | CN | disclosed |
| CN-112358517-A | Benzimidazole derivative BI305 and preparation method and application thereof | 中国人民解放军东部战区总医院 | 2021-02-12 | — | — | CN | disclosed |
| CN-112358517-A | Benzimidazole derivative BI305 and preparation method and application thereof | 中国人民解放军东部战区总医院 | 2021-02-12 | — | — | CN | disclosed |
| CN-112300235-A | Benzimidazole derivative BI321 and preparation method and application thereof | 中国人民解放军东部战区总医院 | 2021-02-02 | — | — | CN | disclosed |
| CN-112300235-A | Benzimidazole derivative BI321 and preparation method and application thereof | 中国人民解放军东部战区总医院 | 2021-02-02 | — | — | CN | disclosed |
| US-20120046303-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-8067613-B2 | Benzimidazole poly(ADP ribose)polymerase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885CYP1A2 3661/4885CYP3A4 3008/4885 |
| US-20120046303-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885CYP1A2 3661/4885CYP3A4 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.